CN103249423A - 预防或治疗缺血/再灌注损伤之后无复流的方法 - Google Patents

预防或治疗缺血/再灌注损伤之后无复流的方法 Download PDF

Info

Publication number
CN103249423A
CN103249423A CN2011800429365A CN201180042936A CN103249423A CN 103249423 A CN103249423 A CN 103249423A CN 2011800429365 A CN2011800429365 A CN 2011800429365A CN 201180042936 A CN201180042936 A CN 201180042936A CN 103249423 A CN103249423 A CN 103249423A
Authority
CN
China
Prior art keywords
arg
phe
lys
dmt
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800429365A
Other languages
English (en)
Chinese (zh)
Inventor
肯尼斯·博罗
D·特拉维斯·威尔逊
罗伯特·A·科鲁纳
莎伦·黒勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heart Association Charity Hospital
Stealth Peptides International Inc
Original Assignee
Heart Association Charity Hospital
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Association Charity Hospital, Stealth Peptides International Inc filed Critical Heart Association Charity Hospital
Priority to CN201510122649.5A priority Critical patent/CN105879008A/zh
Priority to CN201710574500.XA priority patent/CN107569675A/zh
Priority to CN201610616831.0A priority patent/CN106620645A/zh
Publication of CN103249423A publication Critical patent/CN103249423A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
CN2011800429365A 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法 Pending CN103249423A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201510122649.5A CN105879008A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201710574500.XA CN107569675A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201610616831.0A CN106620645A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36313310P 2010-07-09 2010-07-09
US36312910P 2010-07-09 2010-07-09
US61/363,129 2010-07-09
US61/363,133 2010-07-09
US41265510P 2010-11-11 2010-11-11
US61/412,655 2010-11-11
PCT/US2011/043424 WO2012006569A1 (en) 2010-07-09 2011-07-08 Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201510122649.5A Division CN105879008A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201610616831.0A Division CN106620645A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201710574500.XA Division CN107569675A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法

Publications (1)

Publication Number Publication Date
CN103249423A true CN103249423A (zh) 2013-08-14

Family

ID=45441572

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2011800429365A Pending CN103249423A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201610616831.0A Pending CN106620645A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201710574500.XA Pending CN107569675A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201510122649.5A Withdrawn CN105879008A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201610616831.0A Pending CN106620645A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201710574500.XA Pending CN107569675A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法
CN201510122649.5A Withdrawn CN105879008A (zh) 2010-07-09 2011-07-08 预防或治疗缺血/再灌注损伤之后无复流的方法

Country Status (7)

Country Link
US (2) US9345738B2 (cg-RX-API-DMAC7.html)
EP (3) EP4285994A3 (cg-RX-API-DMAC7.html)
JP (5) JP6319738B2 (cg-RX-API-DMAC7.html)
CN (4) CN103249423A (cg-RX-API-DMAC7.html)
CA (1) CA2804404C (cg-RX-API-DMAC7.html)
HK (1) HK1249428A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012006569A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US11724030B2 (en) * 2018-09-21 2023-08-15 Corflow Therapeutics Ag Method and apparatus for diagnosis and treatment of microvascular dysfunction
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
AU2018336787B2 (en) 2017-09-19 2024-05-30 Corflow Therapeutics Ag Intracoronary characterization of microvascular obstruction (MVO) and myocardial infarction
IL305687B2 (en) * 2017-12-15 2024-12-01 Stealth Biotherapeutics Inc Mitochondria-targeting peptides
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN113544138B (zh) * 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) * 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
JPWO2020189593A1 (cg-RX-API-DMAC7.html) 2019-03-20 2020-09-24
RU2711414C1 (ru) * 2019-03-27 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ прогнозирования асимптомного повреждения вещества головного мозга при ангиореконструктивных операциях на сонных артериях
JP7638265B2 (ja) 2019-07-24 2025-03-03 ステルス バイオセラピューティクス インコーポレイテッド 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
EP4792852A2 (en) 2020-05-22 2026-08-19 CorFlow Therapeutics AG Controlled flow infusion microvascular dysfunction diagnostic and therapy
JP7533970B2 (ja) * 2022-01-31 2024-08-14 株式会社ニューギン 遊技機
JP7478453B2 (ja) * 2022-01-31 2024-05-07 株式会社ニューギン 遊技機

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
CN101296704A (zh) * 2005-09-16 2008-10-29 科内尔研究基金会 用于减少cd36表达的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
JPH05301868A (ja) 1992-04-23 1993-11-16 Mitsui Toatsu Chem Inc 虚血性心疾患治療剤
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP1526140B1 (en) * 2002-08-01 2008-11-05 Astellas Pharma Inc. Potassium-dependent sodium-calcium exchanger
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
CN101296704A (zh) * 2005-09-16 2008-10-29 科内尔研究基金会 用于减少cd36表达的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E. EECKHOUT AND M.J. KERN: "The coronary no-reflow phenomenon: a review of mechanisms and therapies", 《EUROPEAN HEART JOURNAL》 *
E. EECKHOUT AND M.J. KERN: "The coronary no-reflow phenomenon: a review of mechanisms and therapies", 《EUROPEAN HEART JOURNAL》, vol. 22, 31 December 2001 (2001-12-31), pages 729 - 739, XP055075269, DOI: doi:10.1053/euhj.2000.2172 *
HAZEL H. SZETO: "Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury", 《ANTIOXIDANTS & REDOX SIGNALING》 *
SHEREIF H ET AL: "No-Reflow Phenomenon", 《CIRCULATION》 *
SUNGHEE CHO ET AL: "A Novel Cell-permeable Antioxidant Peptide, SS31, Attenuates Ischemic Brain Injury by Down-regulating CD36", 《J. BIOL. CHEM》 *

Also Published As

Publication number Publication date
JP2016172781A (ja) 2016-09-29
US20130196921A1 (en) 2013-08-01
JP2013531682A (ja) 2013-08-08
CN105879008A (zh) 2016-08-24
EP2590664A4 (en) 2014-01-15
CN106620645A (zh) 2017-05-10
CA2804404A1 (en) 2012-01-12
EP2590664A1 (en) 2013-05-15
EP4285994A3 (en) 2024-01-17
JP2020114880A (ja) 2020-07-30
JP2019052188A (ja) 2019-04-04
US10322159B2 (en) 2019-06-18
EP2590664B1 (en) 2019-03-27
WO2012006569A1 (en) 2012-01-12
US9345738B2 (en) 2016-05-24
EP3539554A1 (en) 2019-09-18
CA2804404C (en) 2020-10-20
JP6319738B2 (ja) 2018-05-09
JP2022012924A (ja) 2022-01-17
EP4285994A2 (en) 2023-12-06
HK1249428A1 (zh) 2018-11-02
CN107569675A (zh) 2018-01-12
US20170087204A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CN105879008A (zh) 预防或治疗缺血/再灌注损伤之后无复流的方法
JP7382607B2 (ja) 心不全の予防又は処置の方法
US20220280593A1 (en) Methods for performing a coronary artery bypass graft procedure
CN103751763A (zh) 用于预防或治疗血管阻塞损伤的方法
CN104225574A (zh) 用于防止线粒体通透性改变的方法
HK1249406A1 (zh) 芳族阳离子肽和使用它们的方法
HK1178087A (en) Methods for performing a coronary artery bypass graft procedure
HK1178086A (en) Methods for the prevention or treatment of vessel occlusion injury
AU2015221569A1 (en) Methods for performing a coronary artery bypass graft procedure
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
HK1176561A (en) Methods for the prevention or treatment of heart failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130814